Lipoic Acid for MS - A 2022 Review

What is Brain atrophy in MS and why the interest in Lipoic?

Brain atrophy, the gradual loss of brain volume, is quite extensive in MS, nearly 0.5–1.35% per year, far off the limits of normal aging.

Brain MRI atrophy quantification in MS reviewed publications between 1979 and 2017 involving brain atrophy and MS. This review recomended that a standard proceedure be establised. This to move atrophy quantification definitively into clinical practice, effort should be devoted to creating a worldwide standardized protocol for image acquisition not only for research studies, but also for individual patient management.

2018 - group put together in the IK to review potentisl repurposing of existin treatments for other diseases for use with MS.  R ALA was high on the list.
Systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis. ⁽¹⁾ 

Brain atrophy identified as issue in MS. Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study (2) first publishe 2014

Antrophy Definition and Symptoms. (3)